The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | DLBCL in the elderly: a real-world experience in Latin America
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, comments on data from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL), formed to create data from the Hispanic population, which is frequently under-represented in clinical trials. Looking at treatment outcomes in 180 elderly patients with diffuse large B-cell lymphoma (DLBCL), the group observed no major differences in terms of response, progression-free survival (PFS) and overall survival (OS) based on treatment intensity. There was a higher rate of death in these patients, and disease progression and treatment toxicity were the major causes, even with lower intensity treatment regimens. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
AstraZeneca: Research Funding; Roche: Consultancy; TG Therapeutics: Research Funding; Pharmacyclics: Consultancy, Research Funding; Cellectar: Consultancy; Beigene: Consultancy, Research Funding; Janssen: Consultancy; Abbvie: Consultancy, Research Funding.
